Follow the people · Insider
Ezra M. Friedberg
Ezra M. Friedberg files insider transactions with the SEC as a director of Pelthos Therapeutics (PTHS). We hold 3 disclosed purchases and sales filed since 15 September 2016, 2 of them in the last 90 days.
- Files forPTHS
- Disclosed buys and sells3 in all, 2 in the last 90 days
- Last disclosure7 July 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 14 June 2024 — 2 July 2026Director · Pelthos Therapeutics (PTHS)22 Form 4 lines · source: SEC Form 4
- Filed 21 February 2024 — 13 November 2024Director · Chromocell Therapeutics (CHRO)7 Form 4 lines · source: SEC Form 4
- Filed 13 September 2016 — 13 September 2016Director · Kalobios Pharmaceuticals (KBIO)1 Form 4 line · source: SEC Form 4
Everything they disclosed
30 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 534 shares of Pelthos TherapeuticsSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 24 shares of Pelthos TherapeuticsSEC Form 47 July 2026Common Stock · traded 2 July 2026 · filed 7 July 2026
- ▼ sold on the open market 224 shares of Pelthos TherapeuticsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 59 shares of Pelthos TherapeuticsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- had shares withheld for tax on 144 shares of Pelthos TherapeuticsSEC Form 418 May 2026Common Stock · traded 14 May 2026 · filed 18 May 2026
- ▼ sold on the open market 293 shares of Pelthos TherapeuticsSEC Form 46 April 2026Common Stock · traded 2 April 2026 · filed 6 April 2026
- ▼ sold on the open market 265 shares of Pelthos TherapeuticsSEC Form 46 April 2026Common Stock · traded 2 April 2026 · filed 6 April 2026
- was granted 6,450 shares of Pelthos TherapeuticsSEC Form 41 April 2026Common Stock · traded 14 June 2024 · filed 1 April 2026
- was granted 2,454 shares of Pelthos TherapeuticsSEC Form 41 April 2026Common Stock · traded 13 November 2024 · filed 1 April 2026
- was granted 19,108 shares of Pelthos TherapeuticsSEC Form 41 April 2026Common Stock · traded 2 July 2025 · filed 1 April 2026
- ▼ sold on the open market 5,999 shares of Pelthos TherapeuticsSEC Form 426 November 2025Common Stock · traded 25 November 2025 · filed 26 November 2025
- ▼ sold on the open market 2,000 shares of Pelthos TherapeuticsSEC Form 426 November 2025Common Stock · traded 25 November 2025 · filed 26 November 2025
- ▼ sold on the open market 1 share of Pelthos TherapeuticsSEC Form 426 November 2025Common Stock · traded 25 November 2025 · filed 26 November 2025
- ▼ sold on the open market 2,000 shares of Pelthos TherapeuticsSEC Form 426 November 2025Common Stock · traded 25 November 2025 · filed 26 November 2025
- was granted 19,108 shares of Pelthos Therapeutics (a derivative holding)SEC Form 47 July 2025Restricted Stock Units · traded 2 July 2025 · filed 7 July 2025
- was granted 58,230 shares of Pelthos Therapeutics (a derivative holding)SEC Form 47 July 2025Stock Option · traded 2 July 2025 · filed 7 July 2025
- ▲ bought on the open market 40,000 shares of Pelthos Therapeutics (a derivative holding)SEC Form 43 July 2025Series A Convertible Preferred Stock · traded 1 July 2025 · filed 3 July 2025
- ▲ bought on the open market 40,000 shares of Pelthos Therapeutics (a derivative holding)SEC Form 43 July 2025Series A Convertible Preferred Stock · traded 1 July 2025 · filed 3 July 2025
- converted 40,000 shares of Pelthos Therapeutics (a derivative holding)SEC Form 43 July 2025Series A Convertible Preferred Stock · traded 1 July 2025 · filed 3 July 2025
- converted 40,000 shares of Pelthos Therapeutics (a derivative holding)SEC Form 43 July 2025Series A Convertible Preferred Stock · traded 1 July 2025 · filed 3 July 2025
- converted 40,000 shares of Pelthos TherapeuticsSEC Form 43 July 2025Common Stock · traded 1 July 2025 · filed 3 July 2025
- converted 40,000 shares of Pelthos TherapeuticsSEC Form 43 July 2025Common Stock · traded 1 July 2025 · filed 3 July 2025
- was granted 24,533 shares of Chromocell Therapeutics (a derivative holding)SEC Form 415 November 2024Restricted Stock Units · traded 13 November 2024 · filed 15 November 2024
- was granted 64,498 shares of Chromocell Therapeutics (a derivative holding)SEC Form 418 June 2024Restricted Stock Units · traded 14 June 2024 · filed 18 June 2024
- ▲ bought on the open market 16,667 shares of Chromocell TherapeuticsSEC Form 412 March 2024Common Stock · traded 21 February 2024 · filed 12 March 2024
- converted 65,514 shares of Chromocell Therapeutics (a derivative holding)SEC Form 423 February 2024Secured Convertible Promissory Note · traded 21 February 2024 · filed 23 February 2024
- converted 33,136 shares of Chromocell Therapeutics (a derivative holding)SEC Form 423 February 2024Secured Convertible Promissory Note · traded 21 February 2024 · filed 23 February 2024
- exercised options over 13,649 shares of Chromocell TherapeuticsSEC Form 423 February 2024Common Stock · traded 21 February 2024 · filed 23 February 2024
- exercised options over 6,992 shares of Chromocell TherapeuticsSEC Form 423 February 2024Common Stock · traded 21 February 2024 · filed 23 February 2024
- was granted 100,000 shares of Kalobios Pharmaceuticals (a derivative holding)SEC Form 415 September 2016Stock Option (right to buy) · traded 13 September 2016 · filed 15 September 2016
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.